Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MEDI3250 in Healthy Japanese Children
NCT02269488Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen in influenza, sponsored by AstraZeneca. Started Nov 2014; status: completed.
02
Drugs
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02269488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269488.